A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs Arbaclofen (Primary)
  • Indications Muscle spasticity
  • Focus Registrational; Therapeutic Use
  • Acronyms OS440-3004
  • Sponsors Osmotica Pharmaceutical
  • Most Recent Events

    • 05 Mar 2018 Planned End Date changed from 1 Jan 2019 to 1 Apr 2019.
    • 05 Mar 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Jan 2019.
    • 05 Mar 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top